Literature DB >> 12003714

Perianal Crohn's Disease.

Abhijit Basu1, Steven D. Wexner.   

Abstract

Perianal Crohn's disease usually is associated with involvement of another primary site of Crohn's disease. However, there is conflicting evidence on the relationship between proximal disease activity and perianal symptoms. Therefore, although it is reasonable to treat active proximal disease, symptomatic perianal disease may have to be treated on its own right. Hemorrhoids and anal fissures are best treated medically. Fistulae and abscesses are treated with control of sepsis and resolution of inflammation while preserving continence and quality of life. Abscesses require surgical drainage, which needs to be prolonged for healing to be complete. Fistulae may be treated with medications first, especially if the rectum is diseased. Refractory fistulae respond better to surgical treatment and sometimes require fecal diversion. The medical management of patients with perianal Crohn's disease consists of rectal mesalamine, systemic antibi-otics, immunosuppressive agents, and infliximab. The role of infliximab is evolving and it may reduce the need for surgical intervention in some cases. Perianal hygiene and skin protection help to reduce local discomfort.

Entities:  

Year:  2002        PMID: 12003714     DOI: 10.1007/s11938-002-0041-y

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  41 in total

1.  Symposium. Crohn's disease: anal lesions.

Authors:  H E Lockhart-Mummery
Journal:  Dis Colon Rectum       Date:  1975-04       Impact factor: 4.585

2.  Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease.

Authors:  W A Stack; S D Mann; A J Roy; P Heath; M Sopwith; J Freeman; G Holmes; R Long; A Forbes; M A Kamm
Journal:  Lancet       Date:  1997-02-22       Impact factor: 79.321

3.  Perianal abscess in Crohn's disease.

Authors:  F Makowiec; E C Jehle; H D Becker; M Starlinger
Journal:  Dis Colon Rectum       Date:  1997-04       Impact factor: 4.585

4.  Surgical treatment of anorectal fistula in patients with Crohn's disease.

Authors:  D H Levien; J Surrell; W P Mazier
Journal:  Surg Gynecol Obstet       Date:  1989-08

5.  Endorectal advancement flap in perianal Crohn's disease.

Authors:  J S Joo; E G Weiss; J J Nogueras; S D Wexner
Journal:  Am Surg       Date:  1998-02       Impact factor: 0.688

6.  Long-term analysis of the use of transanal rectal advancement flaps for complicated anorectal/vaginal fistulas.

Authors:  G Ozuner; T L Hull; J Cartmill; V W Fazio
Journal:  Dis Colon Rectum       Date:  1996-01       Impact factor: 4.585

7.  Surgical treatment of anorectal complications in Crohn's disease.

Authors:  F Michelassi; M Melis; M Rubin; R D Hurst
Journal:  Surgery       Date:  2000-10       Impact factor: 3.982

8.  Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease.

Authors:  D H Casson; M Eltumi; S Tomlin; J A Walker-Smith; S H Murch
Journal:  Gut       Date:  2000-09       Impact factor: 23.059

9.  Evaluation of surgery for perianal Crohn's fistulas.

Authors:  H J Scott; J M Northover
Journal:  Dis Colon Rectum       Date:  1996-09       Impact factor: 4.585

10.  Surgery for symptomatic hemorrhoids and anal fissures in Crohn's disease.

Authors:  A F Wolkomir; M A Luchtefeld
Journal:  Dis Colon Rectum       Date:  1993-06       Impact factor: 4.585

View more
  3 in total

1.  Management of nonhealing perineal wounds.

Authors:  Jill C Genua; David A Vivas
Journal:  Clin Colon Rectal Surg       Date:  2007-11

Review 2.  Minimally invasive surgery for inflammatory bowel disease: Review of current developments and future perspectives.

Authors:  Philipp-Alexander Neumann; Emile Rijcken
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-05-06

3.  Healing of the perineal wound after proctectomy in Crohn's disease patients: only preoperative perineal sepsis predicts poor outcome.

Authors:  W Li; L Stocchi; F Elagili; R P Kiran; S A Strong
Journal:  Tech Coloproctol       Date:  2017-10-12       Impact factor: 3.781

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.